AR065194A1 - Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio - Google Patents

Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio

Info

Publication number
AR065194A1
AR065194A1 ARP080100493A ARP080100493A AR065194A1 AR 065194 A1 AR065194 A1 AR 065194A1 AR P080100493 A ARP080100493 A AR P080100493A AR P080100493 A ARP080100493 A AR P080100493A AR 065194 A1 AR065194 A1 AR 065194A1
Authority
AR
Argentina
Prior art keywords
heterocyclyl
optionally substituted
cycloalkylalkyl
heteroarylalkyl
cycloalkyl
Prior art date
Application number
ARP080100493A
Other languages
English (en)
Spanish (es)
Inventor
Shifeng Liu
Jianmin Fu
Rajender Kamboj
Mark Wood
Sultan Chowdhury
Qun Sun
Jia Qi
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of AR065194A1 publication Critical patent/AR065194A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ARP080100493A 2007-02-05 2008-02-05 Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio AR065194A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88825307P 2007-02-05 2007-02-05
US91212207P 2007-04-16 2007-04-16

Publications (1)

Publication Number Publication Date
AR065194A1 true AR065194A1 (es) 2009-05-20

Family

ID=39420569

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100493A AR065194A1 (es) 2007-02-05 2008-02-05 Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio

Country Status (12)

Country Link
US (1) US20080194616A1 (OSRAM)
EP (1) EP2079737A1 (OSRAM)
JP (1) JP2010518026A (OSRAM)
AR (1) AR065194A1 (OSRAM)
AU (1) AU2008213836A1 (OSRAM)
BR (1) BRPI0807351A2 (OSRAM)
CA (1) CA2677493A1 (OSRAM)
CL (1) CL2008000369A1 (OSRAM)
MX (1) MX2009008338A (OSRAM)
RU (1) RU2009133336A (OSRAM)
TW (1) TW200838539A (OSRAM)
WO (1) WO2008097991A1 (OSRAM)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101610765A (zh) * 2006-12-18 2009-12-23 卡多兹公司 用于治疗炎症的新组合物
EP2107907B1 (en) * 2006-12-20 2012-02-01 Cardoz AB Combination of pemirolast and ramatroban for use in the treatment of inflammatory disorders
EP2229388A4 (en) * 2008-01-11 2012-03-07 Glenmark Pharmaceuticals Sa CONDENSED PYRIMIDINE DERIVATIVES AS TRPV3 MODULATORS
CN101531638B (zh) * 2008-03-13 2011-12-28 中国科学院广州生物医药与健康研究院 用作雌激素相关受体调节剂的化合物及其应用
US20110092463A1 (en) * 2008-04-07 2011-04-21 Johan Raud Combination for use in the treatment of inflammatory disorders
US8119647B2 (en) 2008-04-23 2012-02-21 Glenmark Pharmaceuticals S.A. Fused pyrimidineone compounds as TRPV3 modulators
CN101628913B (zh) * 2008-07-18 2013-01-23 中国科学院广州生物医药与健康研究院 用作雌激素相关受体调节剂的化合物及其应用
HRP20140754T2 (hr) 2009-06-29 2015-07-17 Incyte Corporation Pirimidinoni kao inhibitori pi3k
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
AR079529A1 (es) * 2009-12-18 2012-02-01 Incyte Corp Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k
WO2011130342A1 (en) 2010-04-14 2011-10-20 Incyte Corporation FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
EP2593434A1 (en) 2010-07-16 2013-05-22 Purdue Pharma LP Pyridine compounds as sodium channel blockers
WO2012087881A1 (en) 2010-12-20 2012-06-28 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
LT3196202T (lt) 2011-09-02 2019-07-10 Incyte Holdings Corporation Heterociklilaminai, kaip pi3k slopikliai
US9630929B2 (en) 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
JP6014155B2 (ja) 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドXenon Pharmaceuticals Inc. ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
US9567331B2 (en) 2011-11-15 2017-02-14 Trustees Of Boston University Pyridopyrimidinone inhibitors of viruses
AU2013203824A1 (en) 2012-03-16 2013-10-03 Purdue Pharma L.P. Substituted pyridines and pryimidines as sodium channel blockers
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
KR101719893B1 (ko) * 2012-05-22 2017-03-24 제넨테크, 인크. N-치환된 벤즈아미드 및 통증의 치료에서 이들의 용도
JP6309519B2 (ja) * 2012-07-06 2018-04-11 ジェネンテック, インコーポレイテッド N置換ベンズアミド及びその使用方法
US9714252B2 (en) 2012-12-20 2017-07-25 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
WO2014153037A1 (en) 2013-03-14 2014-09-25 Genentech, Inc. Substituted triazolopyridines and methods of use thereof
EP2970156B1 (en) 2013-03-15 2018-07-25 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
EP3043787B1 (en) * 2013-09-10 2018-09-05 Chromocell Corporation Sodium channel modulators for the treatment of pain and diabetes
AU2014356967A1 (en) 2013-11-27 2016-07-07 Genentech, Inc. Substituted benzamides and methods of use thereof
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
JP2017525677A (ja) 2014-07-07 2017-09-07 ジェネンテック, インコーポレイテッド 治療用化合物及びその使用方法
CN117736209A (zh) 2015-02-27 2024-03-22 因赛特控股公司 Pi3k抑制剂的盐及其制备方法
CR20170462A (es) * 2015-04-15 2018-02-01 Hoffmann La Roche Piridopirimidinonas y utilización de las mismas como moduladores de receptores nmda
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
MA42118A (fr) 2015-05-22 2018-03-28 Genentech Inc Benzamides substitués et leurs méthodes d'utilisation
MX379846B (es) 2015-06-18 2025-03-11 89Bio Ltd Derivados de 4-bencil y 4-benzoil piperidina sustituidos.
ES2821049T3 (es) 2015-06-18 2021-04-23 89Bio Ltd Derivados de piperidina 1,4 sustituidos
WO2017035271A1 (en) 2015-08-27 2017-03-02 Genentech, Inc. Therapeutic compounds and methods of use thereof
MX386501B (es) 2015-09-28 2025-03-19 Genentech Inc Compuestos terapeuticos y sus metodos de uso
EP3380466A1 (en) 2015-11-25 2018-10-03 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
US10766858B2 (en) 2016-03-30 2020-09-08 Genentech, Inc. Substituted benzamides and methods of use thereof
JP2019532077A (ja) 2016-10-17 2019-11-07 ジェネンテック, インコーポレイテッド 治療用化合物及びその使用方法
CN110546148A (zh) 2017-03-24 2019-12-06 基因泰克公司 作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物
AR114263A1 (es) 2018-02-26 2020-08-12 Genentech Inc Compuestos terapéuticos y métodos para utilizarlos
EP3774801A1 (en) 2018-03-30 2021-02-17 F. Hoffmann-La Roche AG Fused ring hydro-pyrido compounds as sodium channel inhibitors
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
PE20211208A1 (es) 2018-06-01 2021-07-05 Incyte Corp Regimen de dosificacion para el tratamiento de trastornos relacionados con pi3k
CN112533664A (zh) * 2018-06-05 2021-03-19 英凯达治疗公司 使用气雾剂诊断Brugada综合征的方法
MX2022006370A (es) * 2019-11-25 2022-09-07 Amgen Inc Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso.
CN110818709B (zh) * 2019-11-28 2022-09-02 成都大学 一种co2参与下合成嘧啶酮类化合物的方法
CN113292557B (zh) * 2021-05-31 2022-02-11 贵州大学 一种含吲哚单元的吡啶并嘧啶酮类介离子衍生物及其制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63112566A (ja) * 1986-10-28 1988-05-17 Nissan Chem Ind Ltd ピリミジノン誘導体、その製法および殺虫・殺ダニ・殺菌剤
JP2007509150A (ja) * 2003-10-21 2007-04-12 メルク エンド カムパニー インコーポレーテッド 神経障害性疼痛の治療において有用なトリアゾロ−ピリダジン化合物および、この誘導体
AR053713A1 (es) * 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
WO2007002701A2 (en) * 2005-06-27 2007-01-04 Amgen Inc. Anti-inflammatory aryl nitrile compounds
EP1937678B1 (en) * 2005-10-04 2011-07-27 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hiv integrase inhibitors
EP1818058A3 (en) * 2006-02-13 2007-11-07 Astion Pharma A/S Treatment of mmp-mediated dermatological diseases with pemirolast

Also Published As

Publication number Publication date
AU2008213836A1 (en) 2008-08-14
US20080194616A1 (en) 2008-08-14
JP2010518026A (ja) 2010-05-27
RU2009133336A (ru) 2011-03-20
BRPI0807351A2 (pt) 2014-05-20
CA2677493A1 (en) 2008-08-14
MX2009008338A (es) 2009-08-12
EP2079737A1 (en) 2009-07-22
WO2008097991A1 (en) 2008-08-14
TW200838539A (en) 2008-10-01
CL2008000369A1 (es) 2008-04-18

Similar Documents

Publication Publication Date Title
AR065194A1 (es) Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio
AR065081A1 (es) Compuestos de quinazolinona y pirimidona fusionados y composicion farmaceutica
AR056317A1 (es) Compuestos de oxindol y composicion farmaceutica
AR059229A1 (es) Derivados de piperidinilo como moduladores de la actividad del receptor de quimiocina
AR053710A1 (es) Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
AR079814A1 (es) Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
CO6440540A2 (es) Nuevas pirazol-4-n-alcoxicarboxamidas como microbicidas
BRPI0417208A (pt) derivados de 8'-piri(mi)dinil-diidroespiro-[cicloalquilamina]-pirimid o[1,2-ona]pirimidin-6-ona
AR053713A1 (es) Compuestos heterociclicos y sus usos como agentes terapeuticos
MX2009010024A (es) Nuevo compuesto de adenina.
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
ATE205213T1 (de) Pentacyclische verbindungen
MX2009008465A (es) Nuevas 2-aminooxazolinas como ligandos de taar1.
LU90317I2 (fr) Tacrolimus et ses sels et dérivés pharmaceutiquement acceptables
CO5040012A1 (es) Esteres diaril y procesos para su preparacion y composicio- nes herbicidas y disecantes que los contienen
ATE528289T1 (de) 1,2-disubstituierte 4- benzylaminopyrrolidinderivate als für die behandlung von krankheiten wie hyperlipidämie oder arteriosklerose geeignete cetp-inhibitoren
EA201170095A1 (ru) Производные (4-пиридин-4-ил)-1h-(1,3,5) триазин-2-она в качестве ингибирования gsk3-бета для лечения нейродегенеративных заболеваний
AR055878A1 (es) Derivados de ciclopropanocarboxamida
AR065628A1 (es) Compuestos triciclicos de utilidad en el tratamiento de trastornos por carencia de hierro en el organismo
ES2476422T3 (es) Compuestos de piperidina 3,5-sustituida como inhibidores de renina
TW200505922A (en) Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives
EP1640367A4 (en) ISOCHINOLINE-1,3,4-TRION, SYNTHETIC METHOD AND ITS USE
AR073497A1 (es) Compuestos de pirazolilo policiclicos de n-sulfonamido
WO2009044018A9 (fr) Dérivés de 1-0x0-1,2-dihydroisoquinoleine-5-carboxamides et de 4-oxo-3,4-dihydroquinazoline-8-carboxamides, leur préparation et leur application en thérapeutique
MA29559B1 (fr) Derives de 4,5-diarylpyrrole, leur preparation et leur application en therapeutique

Legal Events

Date Code Title Description
FB Suspension of granting procedure